Dec 23 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Acer Therapeutics Inc's drug for treating patients with a type of genetic disorder called urea cycle disorders, according to the health regulator's website. (Reporting by Raghav Mahobe in Bengaluru; Editing by Anil D'Silva)
Acer Therapeutics Inc.
Equities
ACER
US00444P1084
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+2.50% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |